Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T16:22:55.259Z.
Calculation as of: 2026-10-06T16:22:55.259Z.
Quote observation: 2026-10-06T16:20:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
EARNINGS YIELD
N/A
Market Cap
$519.25M
Earnings Yield
N/A
TTM Avg
516.44%
3Y Avg
516.44%
5Y Avg
516.44%
Market Cap
$538.54M
Earnings Yield
0.08%
TTM Avg
0.28%
3Y Avg
0.28%
5Y Avg
0.28%
Market Cap
$540.01M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$548.84M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $528.79M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.68M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $534.64M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $518.16M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 516.44% | 516.44% | 516.44% |
| Delcath Systems, Inc. (DCTH)vs › | $538.54M | 0.08% | 0.28% | 0.28% | 0.28% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.01M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $511.14M | N/A | 8.34% | 8.34% | 8.34% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $548.84M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $546.52M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
